While better new drugs are urgently needed to treat neurodegenerative diseases, developing them is too complex and expensive for big pharmaceutical companies. Research and development that costs millions of dollars can fail at any time and the investment is risky. 
Although some neurodegenerative diseases can now be treated by non-drug methods, the treatment is so cruel that it is likely to cause permanent damage to the patient.
 big pharmaceutical companies cannot be expected to invest in drugs to treat neurodegenerative diseases.